The recent decision by the Trump administration to cancel a $770 million contract with Moderna (MRNA.O) for the development of an avian flu vaccine highlights a troubling trend in the United States’ defense strategy. While military funding remains a priority, the government’s budget allocations seem to disregard the looming threat of pandemics, which have proven to be a significant risk to public health.
Pandemics are no longer the distant threat that many policymakers once dismissed. The COVID-19 pandemic, for instance, resulted in more American deaths than all the nation’s wars combined and imposed an estimated economic burden of $14 trillion, primarily due to lost business revenue, as indicated by research from the University of Southern California. Additionally, lingering health effects contribute an extra $4 trillion to this staggering figure, according to Harvard University economist David Cutler.
The H5N1 virus has already begun to impact food prices, notably causing a surge in egg prices. Moreover, the flu is notorious for its ability to mutate and infect humans, raising the specter of a deadly outbreak reminiscent of the 1918 influenza pandemic, which could lead to an estimated 70 million deaths worldwide. By cutting funds for Moderna's vaccine research, the U.S. government risks exacerbating this public health threat.
The leadership at the U.S. Department of Health and Human Services (HHS) has raised concerns, especially with the appointment of individuals who support discredited anti-vaccine theories. Furthermore, the administration has proposed drastic cuts to the already limited $45 billion budget for the National Institutes of Health (NIH), suggesting a potential reduction of about 40%. This move, combined with significant funding cuts to institutions like Harvard University, which is at the forefront of medical research, paints a grim picture for the future of public health in the U.S.
Interestingly, while the government recently allocated $500 million for the development of universal vaccines targeting multiple virus strains, this funding appears to be directed towards a single project associated with Trump’s former NIH chief. This project relies on outdated technology, and the initiation of clinical trials is not expected until next year, with a Food and Drug Administration (FDA) approval target set for 2029.
In contrast, Moderna's innovative use of messenger RNA (mRNA) technology offers a more promising and scalable solution for vaccine development. The company aimed for FDA approval of its H5 vaccine by early 2026, making it significantly easier to adapt to emerging virus strains and produce millions of doses swiftly. While the recent budget cuts may slow down this critical research, they are unlikely to halt it entirely. Moderna could potentially seek funding from international partners or utilize its own reserves.
However, if an avian flu outbreak occurs, the United States may find itself scrambling for limited vaccine supplies, potentially falling behind other countries in the race to protect public health. This decision to cut funding for vital vaccine research appears to be a shortsighted approach with potentially catastrophic consequences.
The termination of funding for Moderna’s avian flu vaccine development underscores a dangerous neglect of public health priorities in favor of military spending. As the threat of pandemics becomes increasingly evident, it is crucial for the U.S. government to reassess its budget priorities and invest in health security to safeguard its citizens against future health crises.
For more insights and updates on health and technology, follow Robert Cyran on Bluesky.
